The impending departure of founders Ugur Sahin and Özlem Türeci by the end of 2026 has ushered BioNTech into a new strategic era. The market’s initial reaction was severe, with shares plunging 17% on the announcement. While there has been a partial recovery since, the stock continues to trade significantly below its previous levels.
A Shift in Strategic Focus
This leadership change coincides with a deliberate corporate realignment. The supervisory board is actively seeking a successor with expertise in late-stage development and commercial execution, signaling a clear preference for an experienced operator over a scientific pioneer. The stated goal is to transform BioNTech into a commercially robust multi-product company by 2030.
The founders’ exit involves a complex new structure. BioNTech will transfer mRNA technologies and related rights to Sahin and Türeci’s new venture. In return, BioNTech will receive a minority stake, along with future milestone payments and royalties. A binding agreement on this arrangement is slated for signing before the end of the first half of 2026, effectively positioning the new entity as both a potential partner and a future competitor.
Financial Resilience Meets Revenue Headwinds
From a balance sheet perspective, BioNTech remains on solid ground. The company closed 2025 with a substantial war chest of €17.24 billion in liquid assets and investments. Its fourth-quarter 2025 performance also provided a positive surprise, with revenue of €907 million comfortably exceeding consensus estimates of €759 million.
However, management has guided for declining revenues in 2026. Forecasts project sales between €2.0 billion and €2.3 billion, down from €2.87 billion the previous year. This decline is primarily attributed to the ongoing transition of the COVID-19 vaccine market from contractual agreements to private commercial markets, which will continue to pressure Comirnaty revenues. The company does not anticipate meaningful product sales from its oncology portfolio in 2026.
Should investors sell immediately? Or is it worth buying BioNTech?
The Oncology Pipeline: Core to Future Valuation
BioNTech’s substantial potential—and its associated risk—is concentrated in its oncology pipeline. The company expects to have 15 ongoing Phase 3 trials in oncology by year-end. Seven data readouts are scheduled for 2026, five of which are considered pivotal for regulatory submissions. This effort is bolstered by a multi-billion dollar collaboration with Bristol Myers Squibb, valued at up to $11.1 billion.
The critical question for a potential re-rating of the stock in 2026 will be whether clinical data from these studies can successfully pave the way for regulatory approvals.
Analyst Sentiment: Cautious but Constructive
Despite the significant share price correction, analyst coverage remains largely positive, albeit with adjusted price targets.
- Jefferies maintained a Buy rating while lowering its target to $138, suggesting the new leadership could benefit the company long-term through enhanced focus on communication and execution.
- BofA Securities also reiterated a Buy recommendation, reducing its price objective to $128.
- Morgan Stanley confirmed its Overweight rating with a $134 target.
The Path Forward
Structurally, BioNTech is well-positioned with its robust cash reserves and a densely packed clinical calendar. The central theme for investors in the coming months will be the identity of the new CEO and their demonstrated ability to advance the critical oncology pipeline in the post-founder era. The company’s success in navigating this strategic pivot will define its next chapter.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from March 18 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 18.
BioNTech: Buy or sell? Read more here...
